Found: 1
Select item for more details and to access through your institution.
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.
- Published in:
- 2013
- By:
- Publication type:
- journal article